{"id":"W3184066167","doi":"10.1016/j.annonc.2021.07.008","title":"Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"Merck Sharp and Dohme; Eisai; Les Laboratories Pierre Fabre; Merck KGaA; Mount Sylvia Diatomite; Roche; Novartis; Takeda Pharmaceutical Company; AbbVie; Sanofi; Merck; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Pembrolizumab; Tolerability; Interquartile range; Internal medicine; Cohort; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Surgery; Oncology; Adverse effect; Gastroenterology; Clinical trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001450241,0.001577063,0.001978051,0.000320686,0.000459937,0.001003728,0.0008206708,0.001218214,0.006667002],"category_scores_gemma":[0.000818743,0.0005077721,0.001185797,0.0003389324,0.0007603118,0.001205826,0.0003579504,0.002807159,0.001728097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006156059,"about_ca_system_score_gemma":0.000899233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007433167,"about_ca_topic_score_gemma":0.002141271,"domain_scores_codex":[0.9996777,0.0001507182,0.00001265951,0.00007069776,0.0000244892,0.00006393435],"domain_scores_gemma":[0.9996011,0.00008348745,0.00007816732,0.00004117664,0.00002526013,0.000170897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9173442,0.01829787,0.001784038,0.001119089,0.001578223,0.0001554241,0.0001185075,0.0007532855,0.01064733,0.0003352174,0.003457554,0.04440935],"study_design_scores_gemma":[0.9388919,0.05600696,0.002549258,0.00003078635,0.0004296055,0.00008715569,0.00002958431,0.0003563567,0.0004741471,0.0001564192,0.0009752768,0.00001252303],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866501,0.003604033,0.0007118487,0.000645083,0.0002904323,0.002908343,0.001620594,0.0001479103,0.003421669],"genre_scores_gemma":[0.982016,0.003369282,0.001866457,0.001613494,0.0002865177,0.003141135,0.002208108,0.00003890448,0.005460068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006667002,"threshold_uncertainty_score":0.02230328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1210758423075117,"score_gpt":0.4482186709710368,"score_spread":0.3271428286635251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}